Aarts Nikkie, Noordam Raymond, Hofman Albert, Tiemeier Henning, Stricker Bruno H, Visser Loes E
Department of Epidemiology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Internal Medicine, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands.
Int J Clin Pharm. 2016 Oct;38(5):1311-7. doi: 10.1007/s11096-016-0371-9. Epub 2016 Sep 1.
Background Population-based studies investigating indications for antidepressant prescribing mostly rely on diagnoses from general practitioners. However, diagnostic codes might be incomplete and drugs may be prescribed 'off-label' for indications not investigated in clinical trials. Objective We aimed to study indications for antidepressant use based on self-report. Also, we studied the presence of depressive symptoms associated with the self-reported indications. Setting Our study population of antidepressant users was selected based on interview data between 1997 and 2013 from the prospective population-based Rotterdam Study cohort (age >45 years). Method Antidepressant use, self-reported indication for use, and presence of depressive symptoms (Center for Epidemiological Studies Depression Scale) were based on interview. Self-reported indications were categorized by the researchers into officially approved, clinically-accepted and commonly mentioned off-label indications. Main outcome measures A score of 16 and higher on the Center for Epidemiological Studies Depression Scale was considered as indicator for clinically-relevant depressive symptoms. Results The majority of 914 antidepressant users reported 'depression' (52.4 %) as indication for treatment. Furthermore, anxiety, stress and sleep disorders were reported in selective serotonin reuptake inhibitor and other antidepressant users (ranging from 5.9 to 13.3 %). The indication 'pain' was commonly mentioned by tricyclic antidepressant users (19.0 %). Indications were statistically significantly associated with higher depressive symptom scores when compared to non-users (n = 10,979). Conclusions Depression was the main indication for antidepressant treatment. However, our findings suggest that antidepressants are also used for off-label indications, subthreshold disorders and complex situations, which were all associated with clinically-relevant depressive symptoms in the middle-aged and elderly population.
基于人群的抗抑郁药物处方适应证研究大多依赖全科医生的诊断。然而,诊断编码可能不完整,药物可能会被用于临床试验未研究的适应证的“非标签”处方。目的:我们旨在基于自我报告研究抗抑郁药物使用的适应证。此外,我们还研究了与自我报告适应证相关的抑郁症状的存在情况。研究背景:我们的抗抑郁药物使用者研究人群是根据1997年至2013年来自前瞻性基于人群的鹿特丹研究队列(年龄>45岁)的访谈数据选取的。方法:抗抑郁药物使用情况、自我报告的使用适应证以及抑郁症状的存在情况(流行病学研究中心抑郁量表)均基于访谈。研究人员将自我报告的适应证分为官方批准的、临床认可的和常见的非标签适应证。主要结局指标:流行病学研究中心抑郁量表得分16分及以上被视为临床相关抑郁症状的指标。结果:914名抗抑郁药物使用者中的大多数报告“抑郁症”(52.4%)为治疗适应证。此外,选择性5-羟色胺再摄取抑制剂和其他抗抑郁药物使用者报告了焦虑、压力和睡眠障碍(范围从5.9%至13.3%)。三环类抗抑郁药物使用者常提到“疼痛”适应证(19.0%)。与未使用者(n = 10,979)相比,这些适应证与更高的抑郁症状得分在统计学上显著相关。结论:抑郁症是抗抑郁药物治疗的主要适应证。然而,我们的研究结果表明,抗抑郁药物也用于非标签适应证、亚阈值疾病和复杂情况,这些在中年和老年人群中均与临床相关抑郁症状相关。